Independent Grants for Learning & Change (IGLC)
Track 2 - Call for Grant Applications (CGA)
Multi-discipline and Systemic Caring for the Woman Experiencing Menopause: Innovative Decision Making Tools

I. Background

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

When a CGA is issued, it is posted on the IGL&C website (www.pfizer.com/independentgrants) in the Grants Process section and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>✅ United States Only</th>
</tr>
</thead>
</table>

### Applicant Eligibility Criteria:

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

More information on organizations eligible to apply directly for a grant can be found at http://www.pfizer.com/files/IGLC_OrganizationEligibility_effJuly2015.pdf.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, or even different disciplines are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.
III. Requirements

<table>
<thead>
<tr>
<th>Date CGA Issued:</th>
<th>June 1, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area:</td>
<td>Women’s Health</td>
</tr>
</tbody>
</table>
| Specific Area of Interest for this CGA: | Pfizer Global Medical Grants seeks to support innovative educational programming to support optimal and/or appropriate practice interventions regarding care and treatment of women experiencing menopause. Projects should focus on educational resources (e.g. patient-physician shared decision-making tools /innovative apps) to support effective identification of the need for therapeutic intervention and appropriate selection of therapeutic intervention based on presentation.

The learning and change strategy should address helping improve the care of women with menopause by:

- Improving symptom identification (by patients or physicians)
- Improving care systems that showcase and operationalize the wellness visit as a focus for menopausal care
- Innovating patient-physician awareness of various treatment options and modalities for appropriate patients and with appropriate risk-balance assessment

The educational initiative should be focused on primary care practitioners, nurse practitioners, physician assistants, obstetricians and gynecologists, and all other specialists who care for the menopausal woman. Proposals whose educational model is broadly applicable for use in other settings and/or used for resident education will be rated favorably.

In addition, proposals that include the following elements are of interest:

- Completed within a 12 month timeframe
- Developing durable tools, materials (e.g. >1 one time use)
- Intraprofessional collaboration among organizations
- Incorporating the patient perspective
- Innovative in terms of approach and output
- Robust outcomes plan that reflects optimization of care metrics

The utilization of multiple forms of innovation, such as digital communication or social media, to reach the intended audience and to measure change in comprehension and intent to apply learning in practice are critical parts of a successful grant.

Projects that focus on live annual meetings, regional conferences, and speaker series are out of scope.
### Needs Assessment and Background:

Women faced with menopausal symptoms rely on the guidance of trusted clinicians to make sound choices regarding treatment.¹

Menopausal symptoms including moderate to severe vasomotor or vulvovaginal symptoms represent a healthcare burden if left unaddressed. The environment is challenged by patients who are uncomfortable or unwilling to discuss menopausal symptoms with their doctors and practitioners who may not address menopause related care either due to lack of awareness, time or relative prioritization compared to other healthcare needs.

Educational programming that helps patients partner with their clinician through menopause and post-menopause represents an opportunity to reduce fragmented care.

Evidence points to the benefit of comprehensive care, with NAMS recommendations that:

1. Menopause can be viewed as a sentinel event that affords a unique opportunity for a dialog between women and their healthcare providers to evaluate and improve health-related practices (level II)
2. Menopause counseling, including discussion of physiologic changes, assessment of menopause-related symptoms and treatment options, review of screening recommendations and discussion of disease risk reduction strategies and psychosocial issues facilitates informed decision-making among mid-life and older women (level II)
3. By considering women’s values, concerns, and preferences menopause practitioners have the potential to enhance women’s sense of well being not only at menopause but for the rest of their lives.

**References:**

2. Gartoulla P, Worsley R, Bell RJ, Davis SR. “Moderate to Severe Vasomotor and Sexual Symptoms Remain Problematic for Women 60 to 65 Years” Menopause. 2015 Feb 20

### Expected Approximate Monetary Range of Grant Applications:

Individual projects requesting up to $200,000 will be considered.

The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.
| Key Dates: | CGA release date: June 1, 2017  
Grant application due date: July 12, 2017  
*Please note the deadline is midnight Eastern Time (New York, GMT -5).  
Anticipated Grant Award Notification Date: August 23, 2017  
Grant funding will be distributed following execution of fully signed Letter of Agreement  
Period of Performance: Beginning on or after September 1, 2017 |
|---|---|
| How to Submit: | Please go to the website at [www.pfizer.com/independentgrants](http://www.pfizer.com/independentgrants) and click on the button “Go to the Grant System.” Registered users should select the appropriate link under Track 2 – Knowledge Gap  
If this is your first time visiting this site you will be prompted to take the Eligibility Quiz to determine the type of support you are seeking. Please ensure you identify yourself as a first-time user.  
Select the following Educational Area: CGA – Improving Menopausal Care  
Requirements for submission: Complete all required sections of the online application and upload the completed CGA template (see Appendix).  
If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page |
| Questions: | If you have questions regarding this CGA, please direct them in writing to Angelo Carter at [angelo.carter@pfizer.com](mailto:angelo.carter@pfizer.com), with the subject line “Improving Menopausal Care.” |
| Mechanism by which Applicants will be Notified: | All applicants will be notified via email by the dates noted above.  
Applicants may be asked for additional clarification or to make a summary presentation during the review period. |
IV. Terms and Conditions

1. This CGA does not commit Pfizer or its partners to award a grant or a grant of any particular size if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.

2. Pfizer reserves the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety, if it determines it is in the best interest of Pfizer to do so.

3. For compliance reasons and in fairness to all applicants, all communications about the CGA must come exclusively to Pfizer IGL&C. Failure to comply will disqualify applicants.

4. Consistent with its commitment to openness and transparency, Pfizer reports education grants provided to medical, scientific, and patient organizations in the United States. Pfizer reserves the right to announce the details of successful grant application(s) by whatever means insures transparency, such as on the Pfizer website, in presentations, and/or in other public media.

5. Pfizer reserves the right to share with organizations that may be interested in contacting you for further information (e.g., possible collaborations) the title of your proposed project and the name, address, telephone number, and e-mail address of the applicant from the requesting organization.

6. To comply with 42 U.S.C. § 1320a-7h and 42 C.F.R. §§ 403.900-.914 (the Sunshine Act), Provider (sponsor) must provide to Pfizer specific information for the U.S.-licensed physicians and U.S. teaching hospitals (“Covered Recipients,” as defined by applicable law) to whom Provider (sponsor) furnished payments or other transfers of value from the original independent grant awarded by Pfizer. Those payments or transfers-of-value include compensation, reimbursement for expenses, and meals provided to faculty (planners, speakers, investigators, project leads, etc.) and “items of value” (items that possess a discernable value on the open market, such as textbooks) provided to faculty and participants, if those faculty and/or participants meet the definition of Covered Recipient. Provider (sponsor) must submit the required information during the reconciliation process or earlier, upon Pfizer’s request, so Pfizer can meet Sunshine Act reporting commitments. Be advised that Pfizer will not make any payments to any individuals; grant funding shall be paid directly to Provider (sponsor).

   Frequently Asked Questions related to IGLC’s Sunshine Act Reporting Requirements are available on our website (http://www.pfizer.com/files/IGLCsunshineFAQ_updatedJan2016.pdf).

7. No portion of a Pfizer independent grant may be used for food and/or beverages for learners and/or participants in any capacity. Provider (sponsor) will be required to certify during the reconciliation process and/or the periodic collection of Sunshine reporting that funds were not used for food and/or beverages for learners and/or participants.

8. In the performance of all activities related to an independent grant, the Provider (sponsor) and all participants must comply with all applicable Global Trade Control Laws. “Global Trade Control Laws” include, but are not limited to, U.S. Export Administration Regulations; the International Traffic in Arms Regulations; EU export controls on dual-use goods and technology; Financial Sanctions Laws and Restrictive Measures imposed within the framework of the CFSP - Treaty on European Union; and the economic sanctions rules and regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control.
Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
C. Goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
K. Timeline
L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
M. References (outside the 15-page limit)
   • There is no designated format for references
N. Budget (See template available in application)
   • While estimating your budget please keep the following items in mind:
     • Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
     • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
     • A separate Excel file should be uploaded. This does not count toward the page limit.
       • An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
       • At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 15-page limit exclusive of references. If extensive, references may be included on 1-2 additional pages.